Phage therapy for stubborn NTM infection in cystic fibrosis
Part of Digestive system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 6 years or older and have cystic fibrosis.
- You have an NTM lung infection that hasn't cleared after taking antibiotics for more than a year.
- Your doctor plans to treat the infection with phage therapy (special viruses that attack bacteria).
- You will continue taking your usual antibiotics along with the phages.
- You are not pregnant or breastfeeding, and have not had a transplant (organ or bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether an IV medicine called gallium can treat hard-to-treat lung infections (NTM) in adults with cystic fibrosis. It is mainly for people who have not been treated yet for NTM or who have NTM that has not cleared despite antibiotics.
This study looks at how well phage therapy works for people with stubborn bacterial infections, like NTM. If your doctor is already considering phage therapy as part of your care, this trial may help track your response.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
This study looks at whether a urine test (instead of repeated sputum—mucus—from the lungs testing) can help determine who with cystic fibrosis does not have certain lung germs called NTM. If the urine test works, it could reduce the need for lung sample testing while still keeping people safe.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.